logo

Regenxbio Inc (RGNX)



Trade RGNX now with
  Date
  Headline
2/10/2022 5:01:53 PM Wedbush Reiterates Regenxbio Inc (RGNX) At Neutral With $29 Price Target
1/6/2022 7:15:17 AM REGENXBIO Announces FDA Clearance Of IND For Clinical Trial Of RGX-202
12/15/2021 4:29:35 PM Wedbush Starts Regenxbio Inc (RGNX) At Neutral With $29 Price Target
11/22/2021 7:08:29 AM REGENXBIO: FDA Grants Orphan Drug Designation For RGX-202 For Duchenne Muscular Dystrophy
10/1/2021 7:08:30 AM REGENXBIO To Present RGX-314 Data At American Society Of Retina Specialists Annual Meeting
9/13/2021 6:33:23 AM AbbVie, REGENXBIO Form Strategic Deal, To Combine Eye Care And Gene Therapy
2/16/2021 7:22:06 AM REGENXBIO Announces Addnl Positive Interim Phase I/IIa And Long-Term Follow-Up Data Of RGX-314 For Wet AMD
1/8/2021 7:08:54 AM REGENXBIO Prices Public Offering Of 4.26 Mln Shares At $47.00/shr
1/6/2021 4:02:46 PM REGENXBIO Announces Proposed Public Offering Of Common Stock